TRCT
VRAX icon

Tower Research Capital (TRC)’s Virax Biolabs VRAX Stock Holding History

Tower Research Capital (TRC)’s Portfolio VRAX Stock Details VRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Hold
0
– -$20 – 5838
2024
Q4 		– Hold
0
– – – 5603
2022
Q4 		– Sell
-3
Closed -$2K – 6421
2022
Q3 		$2K Buy
+3
New +$4.96K ﹤0.01% 5624

Other funds holding VRAX

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Tower Research Capital (TRC)'s VRAX Position: Q1 2025 in Review

Tower Research Capital (TRC) held its Virax Biolabs (VRAX) position steady in Q1 2025 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5838.

Tower Research Capital (TRC) first reported a position in VRAX in Q3 2022 and has held it in 1 quarter since. The position peaked at $2K in Q3 2022. 4 funds tracked by Wall St. Rank hold VRAX as of Q1 2025.

  • Tower Research Capital (TRC) held 0 shares of Virax Biolabs worth $0 as of Q1 2025.
  • Tower Research Capital (TRC) left its Virax Biolabs share count unchanged in Q1 2025.
  • Virax Biolabs made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2025, its #5838 holding.
  • Tower Research Capital (TRC) first reported a position in Virax Biolabs in Q3 2022 and has held it in 1 quarter since.
  • Tower Research Capital (TRC)'s Virax Biolabs position peaked at $2K in Q3 2022.
  • 4 funds tracked by Wall St. Rank held Virax Biolabs as of Q1 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2025, filed 15 May 2025.